$27.34 -0.3 -0.9%
Last Trade - 16/04/21
| Market Cap | £687.4m |
| Enterprise Value | £493.3m |
| Revenue | £n/a |
| Position in Universe | 2875th / 6850 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. Its lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, with the potential to restore healthy fat metabolism in the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | January 24, 2017 |
| Public Since | June 20, 2019 |
| No. of Shareholders: | 5 |
| No. of Employees: | 21 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 34,770,319 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 601 Gateway Boulevard Suite 350, SOUTH SAN FRANCISCO, 94080, United States |
| Web | https://www.akerotx.com/ |
| Phone | +1 650 4876488 |
| Contact | () |
| Auditors | Deloitte & Touche LLP |
As of 16/04/21, shares in Akero Therapeutics Inc are trading at $27.34, giving the company a market capitalisation of £687.4m. This share price information is delayed by 15 minutes.
Shares in Akero Therapeutics Inc are currently trading at $27.34 and the price has moved by 29.21% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Akero Therapeutics Inc price has moved by -10.94% over the past year.
There are no analysts currently covering Akero Therapeutics Inc.
Akero Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:
Akero Therapeutics Inc does not currently pay a dividend.
Akero Therapeutics Inc does not currently pay a dividend.
Akero Therapeutics Inc does not currently pay a dividend.
To buy shares in Akero Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Akero Therapeutics Inc are currently trading at $27.34, giving the company a market capitalisation of £687.4m.
Here are the trading details for Akero Therapeutics Inc:
Based on an overall assessment of its quality, value and momentum, Akero Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Akero Therapeutics Inc are currently priced at $27.34. At that level they are trading at 0.122% discount to the analyst consensus target price of 0.00.
Analysts covering Akero Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -4.111 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akero Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -20.76%. At the current price of $27.34, shares in Akero Therapeutics Inc are trading at -11.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Akero Therapeutics Inc.
Akero Therapeutics Inc's management team is headed by:
Here are the top five shareholders of Akero Therapeutics Inc based on the size of their shareholding:
